Global Respiratory Syncytial Virus (RSV) Market to Expand at 29.90% CAGR by 2024

World News

MarketResearchReports.Biz presents this most up-to-date research on “OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024”. has announced the addition of a new research report that offers a comprehensive overview of the global respiratory syncytial virus (RSV) market and evaluates the historical as well as the current performance of this market.

The research report, titled “OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis And Forecasts To 2024,” primarily focuses on the therapeutic landscape of the RSV infections across the world.

A human RSV is an enveloped, negative-sense, single-stranded ribonucleic acid (RNA) pneumovirus. It belongs to the paramyxoviridae family and was discovered in 1956. RSV has been identified as the most important cause of lower respiratory tract infections in infants such as bronchiolitis and pneumonia. It also causes upper respiratory tract infections such as the common cold and is a major cause of respiratory infections in elderly people in the global arena.

View Press Release Report at:

According to the market study, the global RSV market, which mainly includes the therapeutics for the treatment of RSV infections, stood at a value of US$640 mn in 2014. Analysts expect this market to expand at an impressive CAGR of 29.90% during the period from 2014 to 2024 and reach an estimated value of US$2.3 bn by the end of the forecast period.

The key regional markets for RSV therapeutics have been identified as 7MM including the U.S., the U. K., France, Japan, Germany, Spain, and Italy in this report. Over the forecast period, the U.S. is projected to lead the global market with a share of 62%. The EU 5 markets, namely the U.K., Germany, Spain, Italy, and France are likely to follow the U.S. and collectively occupy a share of 29% in the overall market during the same period.

For Sample Copy, click here:

The report further states that the launch of new and advanced prophylactic monoclonal antibodies (mAbs) with improved dosing criteria in comparison to Synagis, the most common prescription medication for the treatment of RSV infections, is likely to drive the growth of this market significantly across the world in the coming years. The rising demand for RSV-F vaccine by Novavax, the first adult vaccine offering protection against RSV, is also anticipated to propel this market over the next few years, notes the research study.

The research study also examines the competitive landscape of the global RSV market by analyzing the company profiles of the major enterprises operating in this market. According to it, Gilead Sciences, GlaxoSmithKline, Regeneron, Johnson & Johnson, Ablynx, Novavax, and MedImmune are leading the global RSV market. Other major market participants profiled in this study are Crucell, Immunovaccine Inc., Romark Laboratories, Spring Bank Pharmaceuticals, Ark Biosciences, Biota Pharmaceuticals, Bavarian Nordic, and Meda Pharmaceuticals.

Contact us:

Mr. Nachiket

State Tower

90 State Street, Suite 700

AlbanyScience Articles, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948


E : [email protected]